Rosa Cannistraci
Research Subjects
Research Interests
Rosa Cannistraci has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Gianluca Perseghin
Department of Medicine and Surgery, University of Milano Bicocca, 20126 Milan, Italy
3 shared publications - Stefano Ciardullo
Department of Medicine and Surgery, University of Milano Bicocca, 20126 Milan, Italy
3 shared publications - Emanuele Muraca
Department of Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy
2 shared publications - Francesca Zerbini
Department of Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy
2 shared publications - Alice Oltolini
Policlinico di Monza, Monza, Italy
1 shared publication - Michela Vergani
Department of Medicine and Surgery, University of Milano Bicocca, 20126 Milan, Italy
1 shared publication
Latest Publications
- Open Access
- 18 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6225
The Role of Natriuretic Peptides in the Management of Heart Failure with a Focus on the Patient with Diabetes
Natriuretic peptides (NPs) are polypeptide hormones involved in the homeostasis of the cardiovascular system. They are produced by cardiomyocytes and regulate circulating blood volume and sodium concentration. Clinically, measurements of brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are recommended by international guidelines as evidence is accumulating on their usefulness. They have a high negative predictive value, and in the setting of low NPs, a diagnosis of heart failure (HF) can be safely excluded in both emergency (BNP < 100 pg/mL, NT-proBNP < 300 pg/mL) and outpatient settings (BNP < 35 pg/mL and NT-proBNP < 125 pg/mL). Moreover, the 2023 consensus from the European Society of Cardiology suggests threshold values for inclusion diagnosis. These values are also associated with increased risks of major cardiovascular events, cardiovascular mortality, and all-cause mortality whether measured in inpatient or outpatient settings. Among patients without known HF, but at high risk of developing it (e.g., in the setting of diabetes mellitus, hypertension, or atherosclerotic cardiovascular disease), NPs may be useful in stratifying cardiovascular risk, optimizing therapy, and reducing the risk of developing overt HF. In the diabetes setting, risk stratification with the use of these peptides can guide the physician to a more informed and appropriate therapeutic choice as recommended by guidelines. Notably, NP levels should be carefully interpreted in light of certain conditions that may affect their reliability, such as chronic kidney disease and obesity, as well as demographic variables, including age and sex. In conclusion, NPs are useful in the diagnosis and prognosis of HF, but they also offer advantages in the primary prevention setting.
- 18 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6225
Open AccessThe Role of Natriuretic Peptides in the Management of Heart Failure with a Focus on the Patient with Diabetes
Natriuretic peptides (NPs) are polypeptide hormones involved in the homeostasis of the cardiovascular system. They are produced by cardiomyocytes and regulate circulating blood volume and sodium concentration. Clinically, measurements of brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are recommended by international guidelines as evidence is accumulating on their usefulness. They have a high negative predictive value, and in the setting of low NPs, a diagnosis of heart failure (HF) can be safely excluded in both emergency (BNP < 100 pg/mL, NT-proBNP < 300 pg/mL) and outpatient settings (BNP < 35 pg/mL and NT-proBNP < 125 pg/mL). Moreover, the 2023 consensus from the European Society of Cardiology suggests threshold values for inclusion diagnosis. These values are also associated with increased risks of major cardiovascular events, cardiovascular mortality, and all-cause mortality whether measured in inpatient or outpatient settings. Among patients without known HF, but at high risk of developing it (e.g., in the setting of diabetes mellitus, hypertension, or atherosclerotic cardiovascular disease), NPs may be useful in stratifying cardiovascular risk, optimizing therapy, and reducing the risk of developing overt HF. In the diabetes setting, risk stratification with the use of these peptides can guide the physician to a more informed and appropriate therapeutic choice as recommended by guidelines. Notably, NP levels should be carefully interpreted in light of certain conditions that may affect their reliability, such as chronic kidney disease and obesity, as well as demographic variables, including age and sex. In conclusion, NPs are useful in the diagnosis and prognosis of HF, but they also offer advantages in the primary prevention setting.
- 21 November 2023
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 34 (4) , 963-971
Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: A population-based cohort study
- 21 November 2023
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 34 (4) , 963-971
Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: A population-based cohort study
- Open Access
- 19 July 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (14) , 4783
Differential Association of Sex Hormones with Metabolic Parameters and Body Composition in Men and Women from the United States
Sex hormones impact body composition. Data on the specific impact of each hormone on different body depots in men and women are scarce. The aim of this study is to evaluate the association between testosterone, estradiol and body fat distribution in the general population. This is a population-based cross-sectional study based on data from the 2013–2016 cycles of the National Health and Nutrition Examination Survey. Dual energy X-ray absorptiometry (DXA) and liquid chromatography tandem mass spectrometry were performed on participants aged 18–59 years to evaluate body composition and sex hormone levels, respectively. Weighted multivariable linear regression analyses were performed to evaluate the association between these parameters after adjustment for potential confounders. A total of 6655 participants (3309 males and 3346 females) was included in the analysis. Men with lower testosterone levels were older, had a higher body mass index (BMI) and had a generally unfavorable metabolic profile, while no specific trends were found in women. Among men, testosterone was positively associated with lean body mass and was negatively associated with fat mass and the android/gynoid (A/G) ratio, while an opposite trend was found for estradiol. Among women, testosterone did not impact body composition, while estradiol levels were positively associated with lean mass and were negatively associated with fat mass. Our results support the notion that the impact of different sex hormones on specific fat depots varies substantially between men and women.
- 19 July 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (14) , 4783
Open AccessDifferential Association of Sex Hormones with Metabolic Parameters and Body Composition in Men and Women from the United States
Sex hormones impact body composition. Data on the specific impact of each hormone on different body depots in men and women are scarce. The aim of this study is to evaluate the association between testosterone, estradiol and body fat distribution in the general population. This is a population-based cross-sectional study based on data from the 2013–2016 cycles of the National Health and Nutrition Examination Survey. Dual energy X-ray absorptiometry (DXA) and liquid chromatography tandem mass spectrometry were performed on participants aged 18–59 years to evaluate body composition and sex hormone levels, respectively. Weighted multivariable linear regression analyses were performed to evaluate the association between these parameters after adjustment for potential confounders. A total of 6655 participants (3309 males and 3346 females) was included in the analysis. Men with lower testosterone levels were older, had a higher body mass index (BMI) and had a generally unfavorable metabolic profile, while no specific trends were found in women. Among men, testosterone was positively associated with lean body mass and was negatively associated with fat mass and the android/gynoid (A/G) ratio, while an opposite trend was found for estradiol. Among women, testosterone did not impact body composition, while estradiol levels were positively associated with lean mass and were negatively associated with fat mass. Our results support the notion that the impact of different sex hormones on specific fat depots varies substantially between men and women.